<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: financial condition", fill: "#b8860b"},
{source: "3: financial condition", target: "3: operations", fill: "#b8860b"},
{source: "3: operations", target: "3: severely harmed by", fill: "#b8860b"},
{source: "3: severely harmed by", target: "3: following risks", fill: "#b8860b"},
{source: "3: financial condition", target: "7: expenditures", fill: "#d19fe8"},
{source: "7: expenditures", target: "7: subsequent fiscal", fill: "#d19fe8"},
{source: "7: subsequent fiscal", target: "7: new products under development", fill: "#d19fe8"},
{source: "7: new products under development", target: "7: connection with", fill: "#d19fe8"},
{source: "7: connection with", target: "7: recent acquisition", fill: "#d19fe8"},
{source: "7: recent acquisition", target: "7: Impella CardioSystems AG ", fill: "#d19fe8"},
{source: "7: Impella CardioSystems AG ", target: "7: future periods", fill: "#d19fe8"},
{source: "7: expenditures", target: "8: expenditures", fill: "#a50b5e"},
{source: "8: expenditures", target: "8: costs associated with", fill: "#a50b5e"},
{source: "8: costs associated with", target: "8: clinical trials continuing", fill: "#a50b5e"},
{source: "8: clinical trials continuing", target: "8: development", fill: "#a50b5e"},
{source: "8: development", target: "8: approvals commencing commercial manufacturing", fill: "#a50b5e"},
{source: "8: expenditures", target: "9: expenditures", fill: "#fffafa"},
{source: "9: expenditures", target: "9: difficult", fill: "#fffafa"},
{source: "9: difficult", target: "9: accurately", fill: "#fffafa"},
{source: "9: accurately", target: "9: cost overruns may", fill: "#fffafa"},
{source: "9: expenditures", target: "11: necessary funds", fill: "#d2691e"},
{source: "11: necessary funds", target: "11: commercialize", fill: "#d2691e"},
{source: "11: commercialize", target: "11: new products", fill: "#d2691e"},
{source: "11: new products", target: "11: additional funds will", fill: "#d2691e"},
{source: "11: additional funds will", target: "11: available on commercially", fill: "#d2691e"},
{source: "11: necessary funds", target: "15: the AbioCor AbioCor II ", fill: "#f5f5dc"},
{source: "15: the AbioCor AbioCor II ", target: "15: enhancements", fill: "#f5f5dc"},
{source: "15: enhancements", target: "15: regulatory", fill: "#f5f5dc"},
{source: "15: regulatory", target: "15: anticipation", fill: "#f5f5dc"},
{source: "15: anticipation", target: "15: manufacturing", fill: "#f5f5dc"},
{source: "15: manufacturing", target: "15: facilities", fill: "#f5f5dc"},
{source: "15: facilities", target: "15: establishment", fill: "#f5f5dc"},
{source: "15: establishment", target: "15: international", fill: "#f5f5dc"},
{source: "15: international", target: "15: deliveries", fill: "#f5f5dc"},
{source: "15: deliveries", target: "15: competitive", fill: "#f5f5dc"},
{source: "15: competitive", target: "15: introductions", fill: "#f5f5dc"},
{source: "15: introductions", target: "15: competitors", fill: "#f5f5dc"},
{source: "15: competitors", target: "15: conditions", fill: "#f5f5dc"},
{source: "15: conditions", target: "15: health care industry", fill: "#f5f5dc"},
{source: "15: health care industry", target: "15: containment efforts", fill: "#f5f5dc"},
{source: "15: containment efforts", target: "15: reimbursement policies", fill: "#f5f5dc"},
{source: "15: the AbioCor AbioCor II ", target: "28: new strategies", fill: "#92a1cf"},
{source: "28: new strategies", target: "28: regularly introducing enhancements", fill: "#92a1cf"},
{source: "28: regularly introducing enhancements", target: "28: product line extensions", fill: "#92a1cf"},
{source: "28: product line extensions", target: "28: product expansion within", fill: "#92a1cf"},
{source: "28: product expansion within", target: "28: markets through", fill: "#92a1cf"},
{source: "28: markets through", target: "28: acquisition", fill: "#92a1cf"},
{source: "28: acquisition", target: "28: existing companies whose products may", fill: "#92a1cf"},
{source: "28: existing companies whose products may", target: "28: additional development", fill: "#92a1cf"},
{source: "28: additional development", target: "28: clinical analysis", fill: "#92a1cf"},
{source: "28: clinical analysis", target: "28: regulatory approval", fill: "#92a1cf"},
{source: "28: regulatory approval", target: "28: expanding sales", fill: "#92a1cf"},
{source: "28: expanding sales", target: "28: products within", fill: "#92a1cf"},
{source: "28: products within", target: "28: international markets", fill: "#92a1cf"},
{source: "28: international markets", target: "28: separate regulatory approvals", fill: "#92a1cf"},
{source: "28: separate regulatory approvals", target: "28: seeking new categories", fill: "#92a1cf"},
{source: "28: seeking new categories", target: "28: support with", fill: "#92a1cf"},
{source: "28: support with", target: "28: technology", fill: "#92a1cf"},
{source: "28: new strategies", target: "51: precise high quality manufacturing", fill: "#0095b6"},
{source: "51: precise high quality manufacturing", target: "55: manufacture", fill: "#00b7eb"},
{source: "55: manufacture", target: "55: accordance with necessary quality standards", fill: "#00b7eb"},
{source: "55: accordance with necessary quality standards", target: "55: operations may", fill: "#00b7eb"},
{source: "55: operations may", target: "55: negatively affected", fill: "#00b7eb"},
{source: "55: manufacture", target: "START_HERE", fill: "#00b7eb"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_design">Product design</a></td>
      <td>Product design as a verb is to create a new product to be sold by a business to its customers. A very broad coefficient and effective generation and development of ideas through a process that leads to new products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diversification_(marketing_strategy)">Diversification (marketing strategy)</a></td>
      <td>Diversification is a corporate strategy to enter into a new products or product lines, new services or new markets, involving substantially different skills, technology and knowledge.\nDiversification is one of the four main growth strategies defined by Igor Ansoff in the Ansoff Matrix:\nAnsoff pointed out that a diversification strategy stands apart from the other three strategies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_acquisition">Language acquisition</a></td>
      <td>Language acquisition is the process by which humans acquire the capacity to perceive and comprehend language (in other words, gain the ability to be aware of language and to understand it), as well as to produce and use words and sentences to communicate.\nLanguage acquisition involves structures, rules and representation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Second-language_acquisition">Second-language acquisition</a></td>
      <td>Second-language acquisition (SLA), sometimes called second-language learning — otherwise referred to as L2 (language 2) acquisition, is the process by which people learn a second language. Second-language acquisition is also the scientific discipline devoted to studying that process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Timeline_of_Apple_Inc._products">Timeline of Apple Inc. products</a></td>
      <td>This timeline of Apple Inc. products is a list of all stand-alone Apple II, Macintosh, and other computers, as well as computer peripherals, expansion cards, ancillary products, and consumer electronics sold by Apple Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_innovation">Product innovation</a></td>
      <td>Product innovation is the creation and subsequent introduction of a good or service that is either new, or an improved version of previous goods or services. This is broader than the normally accepted definition of innovation that includes the invention of new products which, in this context, are still considered innovative.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phase-gate_process">Phase-gate process</a></td>
      <td>A phase-gate process (also referred to as a stage-gate process or waterfall process) is a project management technique in which an initiative or project (e.g., new product development, software development, process improvement, business change) is divided into distinct stages or phases, separated by decision points (known as gates).\nAt each gate, continuation is decided by (typically) a manager, steering committee, or governance board.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_strategy">Product strategy</a></td>
      <td>Product strategy defines the high-level plan for developing and marketing a product, how the product supports the business strategy and goals, and is brought to life through product roadmaps. A product strategy describes a vision of the future with this product, the ideal customer profile and market to serve, go-to-market and positioning (marketing), thematic areas of investment, and measures of success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Burger_King_products">Burger King products</a></td>
      <td>When the predecessor of international fast food restaurant chain Burger King (BK) first opened in 1953, its menu predominantly consisted of hamburgers, French fries, soft drinks, milkshakes, and desserts. After being acquired by its Miami, Florida franchisees and renamed in 1954, BK began expanding its menu by adding the Whopper sandwich in 1957, and has since added non-beef items such as chicken, fish, and vegetarian offerings, including salads and meatless sandwiches.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Knowledge_acquisition">Knowledge acquisition</a></td>
      <td>Knowledge acquisition is the process used to define the rules and ontologies required for a knowledge-based system. The phrase was first used in conjunction with expert systems to describe the initial tasks associated with developing an expert system, namely finding and interviewing domain experts and capturing their knowledge via rules, objects, and frame-based ontologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Rules_of_Acquisition">Rules of Acquisition</a></td>
      <td>In the fictional Star Trek universe, the Rules of Acquisition are a collection of sacred business proverbs of the ultra-capitalist race known as the Ferengi.\nThe first mention of rules in the Star Trek universe was in "The Nagus", an episode of the TV series Star Trek: Deep Space Nine (Season 1, Episode 10).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Target_acquisition">Target acquisition</a></td>
      <td>Target acquisition is the detection and identification of the location of a target in sufficient detail to permit the effective employment of lethal and non-lethal means. The term is used for a broad area of applications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Resource_acquisition_is_initialization">Resource acquisition is initialization</a></td>
      <td>Resource acquisition is initialization (RAII) is a programming idiom used in several object-oriented, statically-typed programming languages to describe a particular language behavior.  In RAII, holding a resource is a class invariant, and is tied to object lifetime.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_acquisition_device">Language acquisition device</a></td>
      <td>The Language Acquisition Device (LAD) is a claim from language acquisition research proposed by Noam Chomsky in the 1960s. The LAD concept is a purported instinctive mental capacity which enables an infant to acquire and produce language.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proposed_acquisition_of_Twitter_by_Elon_Musk">Proposed acquisition of Twitter by Elon Musk</a></td>
      <td>On April 14, 2022, business magnate Elon Musk offered to purchase American social media company Twitter, Inc., for $43 billion, after previously acquiring 9.1 percent of the company's stock for $2.64 billion, becoming its largest shareholder. Twitter had then invited Musk to join their board of directors, which Musk at first accepted before subsequently declining.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_royale">Manufacture royale</a></td>
      <td>Manufacture Royale is a Swiss luxury watch brand. Founded in the eighteenth century, the brand was revived in 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ABIOMED INC      ITEM 1A  RISK FACTORS        An <font color="blue">investment</font> in our <font color="blue"><font color="blue">common stock</font> involves</font> a high degree of risk</td>
    </tr>
    <tr>
      <td><font color="blue">Current     </font>and prospective <font color="blue">investors should</font> <font color="blue">carefully</font> consider each of the risks and     <font color="blue"><font color="blue">uncertainties</font> described</font> in this section and all of the other information in     this Report</td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font>     could be <font color="blue">severely harmed by</font> any of the <font color="blue">following risks</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of     our <font color="blue"><font color="blue">common stock</font> <font color="blue">could decline</font></font> if any of these risks and <font color="blue">uncertainties</font>     develop <font color="blue">into actual events</font></td>
    </tr>
    <tr>
      <td>We do not operate at a profit and cannot be assured of <font color="blue">future <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>We  have had net losses in each of the <font color="blue">past three fiscal years</font></td>
    </tr>
    <tr>
      <td>We are     committed to making large <font color="blue">expenditures</font> in fiscal 2007 and <font color="blue">subsequent fiscal</font>     years for our <font color="blue"><font color="blue">new products</font> under <font color="blue">development</font></font>, including those acquired in     <font color="blue">connection with</font> our <font color="blue">recent <font color="blue">acquisition</font></font> of Impella CardioSystems, AG, (now     Impella CardioSystems GmbH, a Division of ABIOMED) which may result in     losses in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">expenditures</font> include <font color="blue">costs associated with</font>     performing clinical trials, continuing our research and <font color="blue">development</font> relating     to our <font color="blue"><font color="blue">new products</font> under <font color="blue">development</font></font>, seeking <font color="blue">regulatory</font> approvals and, if     we  receive  these  approvals, commencing commercial <font color="blue">manufacturing</font> and     marketing</td>
    </tr>
    <tr>
      <td>The  amount of these <font color="blue">expenditures</font> is <font color="blue">difficult</font> to forecast     <font color="blue">accurately</font>, and <font color="blue">cost overruns may</font> occur</td>
    </tr>
    <tr>
      <td>We plan to fund a portion of these     <font color="blue">expenditures</font> from our <font color="blue">existing financial resources</font> and <font color="blue">revenues from</font> AB5000,     BVS and Impella <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>We cannot be sure that we will have the     <font color="blue"><font color="blue">necessary</font> funds</font> to develop and <font color="blue">commercialize</font> our <font color="blue">new products</font>, or that     <font color="blue"><font color="blue">additional</font> funds will</font> be <font color="blue"><font color="blue">available on</font> <font color="blue">commercially</font></font> acceptable terms, if at     all</td>
    </tr>
    <tr>
      <td>In the event that we are unable to obtain the <font color="blue">necessary</font> funding to     develop  and <font color="blue">commercialize</font> our products, our business may be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Our operating results <font color="blue">may fluctuate unpredictably</font></td>
    </tr>
    <tr>
      <td>Our annual and quarterly operating results have <font color="blue">fluctuated historically</font> and     we expect these <font color="blue">fluctuations</font> to continue</td>
    </tr>
    <tr>
      <td>Among the factors that may cause     our operating results to fluctuate are:           •   costs we incur developing and testing the AbioCor, AbioCor II and     other <font color="blue">new products</font> or product <font color="blue">enhancements</font>;           •   the timing of <font color="blue">regulatory</font> actions, such as <font color="blue">product approval</font>s or     recalls;           •   costs we incur in <font color="blue">anticipation</font> of future sales, such as inventory     purchases, expansion of <font color="blue">manufacturing</font> <font color="blue">facilities</font>, or <font color="blue">establishment</font> of     <font color="blue">international</font> sales offices;           •   the timing of customer orders and <font color="blue">deliveries</font>;           •   <font color="blue">competitive</font> changes, such as price changes or new product     <font color="blue">introductions</font> that we or our <font color="blue"><font color="blue">competitor</font>s</font> may make; and           •   economic <font color="blue">conditions</font> in the <font color="blue">health care industry</font> and the state of cost     <font color="blue">containment efforts</font>, including <font color="blue"><font color="blue">reimbursement</font> policies</font></td>
    </tr>
    <tr>
      <td>We believe that period-to-period <font color="blue">comparison</font>s of our historical and future     results will not <font color="blue">necessarily</font> be <font color="blue">meaningful</font>, and that <font color="blue">investors should</font> not     rely  on them as an <font color="blue">indication</font> of <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>To the extent we     experience the factors described above, our future operating results may not     meet the <font color="blue">expectations</font> of <font color="blue">securities analysts</font> or investors from time to time,     which may cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>Our <font color="blue">principal products</font> and <font color="blue">current primary source</font> of revenues, the AB5000,     BVS  5000  and  Impella <font color="blue">circulatory assist products</font>, are vulnerable to     <font color="blue">competitive</font> pressures, disruptions in sales, <font color="blue">continuing review</font> and extensive     <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We believe that we <font color="blue">will continue</font> to <font color="blue">rely heavily</font>     on these products for at least the <font color="blue">next several years until</font> we                                           10     ______________________________________________________________________       obtain <font color="blue">regulatory</font> approval for <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>In the event that a <font color="blue">competitor</font>     were to <font color="blue">introduce new</font> <font color="blue">treatments</font>, products and <font color="blue">technologies</font> which compete     with our products, add new features to their existing products or reduce     their  prices  to  make  their products more <font color="blue">financially</font> attractive to     customers, our revenue from our AB5000, BVS 5000 and Impella <font color="blue">products could</font>     decline</td>
    </tr>
    <tr>
      <td>For example, in the event of the expansion of <font color="blue">technologies</font>, which     <font color="blue">allow heart surgical procedures</font> to be performed <font color="blue">without stopping</font> the heart,     a  reduction  in the market for the AB5000 and BVS 5000 <font color="blue">products could</font>     <font color="blue">potentially</font> result</td>
    </tr>
    <tr>
      <td>Further, the AB5000 and BVS 5000 products are subject to     stringent and continuing FDA and other <font color="blue">regulatory</font> <font color="blue">requirements</font>, including     <font color="blue">compliance with</font> the QSR, <font color="blue">adverse event</font> reporting, <font color="blue">prohibitions on promoting</font>     the  products for <font color="blue">unapproved uses</font>, and <font color="blue">continued inspection</font> and market     <font color="blue">surveillance by</font> the FDA If our products are recalled or <font color="blue">otherwise withdrawn</font>     from the market, our revenues would likely decline, which would hurt our     business</td>
    </tr>
    <tr>
      <td>In addition, variations in the quantity and timing of sales of our     new AB5000 consoles have a <font color="blue">disproportionate</font> effect on our revenues, because     the price of the console is <font color="blue"><font color="blue">substantially</font> greater than</font> the price of our     <font color="blue">disposable <font color="blue">blood pumps</font></font></td>
    </tr>
    <tr>
      <td>If we cannot maintain and increase our disposable     blood pump <font color="blue">revenues from</font> our AB5000 and BVS 5000 product line, our overall     business and <font color="blue">financial condition</font> could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product revenues increased</font> in fiscal 2006 by 14prca in <font color="blue">comparison</font> to fiscal     2005 and in fiscal 2005 our <font color="blue">product revenues increased</font> by 51prca in <font color="blue">comparison</font>     to fiscal 2004</td>
    </tr>
    <tr>
      <td>To maintain or increase <font color="blue">revenues from</font> sales of our current     products, we may be required to <font color="blue">adopt new sales</font> and <font color="blue">marketing strategies</font>,     some of which may require <font color="blue">expending <font color="blue">additional</font> capital resources</font>, or execute     on  <font color="blue">existing strategies</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">new strategies</font> we may adopt or execute on     include:           •   regularly introducing <font color="blue">enhancements</font> and <font color="blue">product line extensions</font>;           •   <font color="blue">product expansion within</font> our <font color="blue">markets through</font> the <font color="blue">acquisition</font> of     <font color="blue">existing companies whose <font color="blue">products may</font></font> require <font color="blue">additional</font> <font color="blue">development</font> or     <font color="blue">clinical analysis</font> for <font color="blue">regulatory</font> approval;           •   <font color="blue">expanding sales</font> of our AB5000, BVS 5000 and Impella <font color="blue">products within</font>     <font color="blue">international</font> markets, some of which require separate <font color="blue">regulatory</font> approvals;     and           •   <font color="blue">seeking new categories</font> of patients to <font color="blue">support with</font> our <font color="blue">technology</font>     platform</td>
    </tr>
    <tr>
      <td>In the event that we are <font color="blue">unsuccessful</font> in carrying out these <font color="blue">new strategies</font>,     our revenues may decline</td>
    </tr>
    <tr>
      <td>We  may  not  be  successful  in  expanding  our <font color="blue"><font color="blue">sales <font color="blue">activities</font></font> into</font>     <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>We are seeking to expand our <font color="blue">international</font> sales of the AB5000, BVS and     Impella <font color="blue">circulatory assist systems by recruiting direct sales</font> and support     teams for <font color="blue">selected countries</font> in Europe</td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> <font color="blue">operations</font> will be     subject to a number of risks, which may vary from the risks we experience in     the US, including:           •   our ability to continue to increase our <font color="blue">global <font color="blue">distribution</font></font>;           •   the need to obtain <font color="blue">regulatory</font> approvals in <font color="blue">foreign countries</font> before     our <font color="blue">products may</font> be sold or used;           •   <font color="blue">longer sales cycles</font>;           •   <font color="blue">dependence on local distributors</font>;           •   limited protection of <font color="blue"><font color="blue">intellectual</font> property rights</font>;           •   <font color="blue">difficult</font>y in <font color="blue">collecting accounts receivable</font>;           •   <font color="blue">fluctuations</font> in the values of <font color="blue">foreign currencies</font>; and           •   political and <font color="blue">economic instability</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue"><font color="blue">effective</font>ly</font> expand</font> our <font color="blue">sales <font color="blue">activities</font></font> in <font color="blue">international</font>     markets, our results of <font color="blue">operations</font> could be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>11     ______________________________________________________________________       We  depend  on  third  <font color="blue">party <font color="blue">reimbursement</font></font> to our customers for market     <font color="blue">acceptance</font>  of  our  products</td>
    </tr>
    <tr>
      <td>If  <font color="blue"><font color="blue">third party</font> payers fail</font> to provide     <font color="blue">appropriate levels</font> of <font color="blue">reimbursement</font> for purchase and use of our products,     our <font color="blue"><font color="blue">profitability</font> would</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Sales of medical products largely depend on the <font color="blue">reimbursement</font> of patients’     medical expenses by <font color="blue">government</font> health care programs and private health     insurers</td>
    </tr>
    <tr>
      <td>The cost of our AB5000 and BVS 5000 systems is substantial, and we     anticipate that the cost of implanting the AbioCor in a <font color="blue">patient will also</font> be     substantial</td>
    </tr>
    <tr>
      <td>Without the financial support of the <font color="blue">government</font> <font color="blue">reimbursement</font>     for CMS <font color="blue">patient care</font> or <font color="blue">third party</font> insurers’ payments for <font color="blue">patient care</font>, the     market  for our <font color="blue">products will</font> be limited</td>
    </tr>
    <tr>
      <td>Medical products and devices     incorporating new <font color="blue">technologies</font> are closely examined by <font color="blue">government</font>s and     <font color="blue">private insurers</font> to determine whether the products and <font color="blue">devices will</font> be     covered by <font color="blue">reimbursement</font>, and if so, the level of <font color="blue">reimbursement</font> which may     apply</td>
    </tr>
    <tr>
      <td>We cannot be sure that <font color="blue"><font color="blue"><font color="blue">third party</font> payors</font> will reimburse sales</font> of our     products now under <font color="blue">development</font>, or <font color="blue">enable us</font> to <font color="blue">sell them at profitable</font>     prices</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be sure that <font color="blue"><font color="blue">third party</font> payors</font> <font color="blue">will continue</font> the     <font color="blue">current level</font> of <font color="blue">reimbursement</font> to physicians and <font color="blue">medical centers</font> for use of     the  AB5000 and BVS 5000 products</td>
    </tr>
    <tr>
      <td>Any reduction in the amount of this     <font color="blue">reimbursement</font> could harm our business</td>
    </tr>
    <tr>
      <td>The federal <font color="blue">government</font> and <font color="blue">private insurers</font> have considered ways to change,     and have changed, the manner in <font color="blue">which health care services</font> are provided and     paid for <font color="blue">in the US </font>In the future, it is possible that the <font color="blue">government</font> may     institute  price  controls and further limits on <font color="blue">Medicare and Medicaid     </font>spending</td>
    </tr>
    <tr>
      <td>These controls and <font color="blue">limits <font color="blue">could affect</font></font> the payments we collect     from sales of our products</td>
    </tr>
    <tr>
      <td>Internationally, medical <font color="blue">reimbursement</font> systems     vary  <font color="blue"><font color="blue">significant</font>ly</font>,  with  some <font color="blue">medical centers</font> having fixed budgets,     <font color="blue">regardless</font> of levels of <font color="blue">patient treatment</font>, and other countries requiring     <font color="blue">application</font> for, and approval of, <font color="blue">government</font> or third <font color="blue">party <font color="blue">reimbursement</font></font></td>
    </tr>
    <tr>
      <td>Even if we succeed in bringing our <font color="blue">new products</font> to market, <font color="blue">uncertainties</font>     regarding future health care policy, legislation and regulation, as well as     private market practices, <font color="blue">could affect</font> our ability to sell our products in     <font color="blue">commercially</font> acceptable <font color="blue">quantities at profitable prices</font></td>
    </tr>
    <tr>
      <td>Prior to approving coverage for new <font color="blue">medical devices</font>, most <font color="blue"><font color="blue">third party</font> payors</font>     require  evidence  that  the product has received FDA approval, is not     <font color="blue">experimental</font>,  and  is  <font color="blue">medically</font>  <font color="blue">necessary</font> for the <font color="blue">specific patient</font></td>
    </tr>
    <tr>
      <td>Increasingly, <font color="blue"><font color="blue">third party</font> payors</font> require evidence that the devices being     used are cost-<font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Our Impella, AbioCor and other products under     <font color="blue">development</font> may not meet these or future criteria, which <font color="blue">could hurt</font> our     ability to market and sell these products</td>
    </tr>
    <tr>
      <td>If we fail to achieve and maintain the high <font color="blue">manufacturing</font> standards that our     products require or if we are unable to develop <font color="blue">additional</font> <font color="blue">manufacturing</font>     <font color="blue">capacity</font>, we will not be successful</td>
    </tr>
    <tr>
      <td>Our products require precise, high quality <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>Our failure to     achieve and maintain these high <font color="blue">manufacturing</font> standards, including the     incidence of <font color="blue">manufacturing</font> errors, design defects or component failures,     could result in <font color="blue">patient injury</font> or death, product recalls or <font color="blue">withdrawals</font>,     delays or failures in <font color="blue">product testing</font> or delivery, cost overruns or other     problems that <font color="blue">could seriously hurt</font> our business</td>
    </tr>
    <tr>
      <td>We have from time to time     <font color="blue">voluntarily recalled <font color="blue">certain products</font></font></td>
    </tr>
    <tr>
      <td>Despite our very high <font color="blue">manufacturing</font>     standards, we <font color="blue">cannot completely eliminate</font> the risk of errors, defects or     failures</td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue">manufacture</font> the AB5000, BVS 5000 and Impella     Recover  products  in accordance with <font color="blue">necessary</font> quality standards, our     business and results of <font color="blue">operations</font> may be <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>The  AbioCor involves even greater <font color="blue">manufacturing</font> complexities than our     <font color="blue">current commercial products</font></td>
    </tr>
    <tr>
      <td><font color="blue">The AbioCor </font>must be <font color="blue"><font color="blue">significant</font>ly</font> more durable     and meet different standards, which may be more <font color="blue">difficult</font> to achieve, than     those  that  apply  to  our  <font color="blue">current product line</font></td>
    </tr>
    <tr>
      <td>If we are unable to     <font color="blue">manufacture</font>  the AbioCor or other <font color="blue"><font color="blue">future products</font> on</font> a <font color="blue"><font color="blue">timely basis</font> at</font>     acceptable  quality  and  cost  and in <font color="blue">commercial quantities</font>, or if we     experience <font color="blue">unanticipated technological problems</font> or delays in production, our     business will suffer</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of our products is and <font color="blue">will continue</font> to be complex and     costly, requiring a number of <font color="blue">separate processes</font> and <font color="blue">components</font></td>
    </tr>
    <tr>
      <td><font color="blue">Achieving     </font>precision and <font color="blue">quality control</font> requires skill and <font color="blue">diligence by</font> our                                           12     ______________________________________________________________________       personnel</td>
    </tr>
    <tr>
      <td>Further, to be successful, we believe we will need to increase     our <font color="blue">manufacturing</font> <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">difficult</font>ies in <font color="blue">scaling up</font>     <font color="blue">manufacturing</font> of our <font color="blue">new products</font>, including problems related to product     yields, <font color="blue">quality control</font> and assurance, component and <font color="blue">service availability</font>,     adequacy of <font color="blue">control policies</font> and procedures, and lack of <font color="blue">skilled personnel</font></td>
    </tr>
    <tr>
      <td>If  we  cannot  hire,  train and retain enough experienced and capable     scientific  and  technical  workers, we may not be able to <font color="blue">manufacture</font>     <font color="blue">sufficient quantities</font> of our current or <font color="blue"><font color="blue">future products</font> at</font> an acceptable     cost and on time, which could limit market <font color="blue">acceptance</font> of our products or     <font color="blue">otherwise damage</font> our business</td>
    </tr>
    <tr>
      <td>If our <font color="blue">suppliers cannot provide</font> the <font color="blue">components</font> we require, our ability to     <font color="blue">manufacture</font> our <font color="blue">products could</font> be harmed</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely <font color="blue">on <font color="blue">third party</font></font> suppliers</font> to provide us with certain <font color="blue">components</font> used     in our existing and other products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Relying <font color="blue">on <font color="blue">third party</font></font>     suppliers  makes  us  vulnerable  to  component  part  failures and to     <font color="blue">interruptions</font> in supply, either of <font color="blue">which could impair</font> our ability to conduct     <font color="blue"><font color="blue">clinical test</font>s</font> or to ship our products to our <font color="blue">customers on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>Using <font color="blue"><font color="blue">third party</font> vendors</font> makes it <font color="blue">difficult</font> and <font color="blue">sometimes impossible</font> for us     to test fully certain <font color="blue">components</font>, such as <font color="blue">components</font> on circuit boards,     maintain <font color="blue">quality control</font>, manage inventory and <font color="blue">production schedules</font> and     control  <font color="blue">production costs</font></td>
    </tr>
    <tr>
      <td>Vendor <font color="blue">lead times</font> to <font color="blue">supply us with ordered</font>     <font color="blue">components</font> vary <font color="blue"><font color="blue">significant</font>ly</font> and can <font color="blue">exceed six months</font> or more</td>
    </tr>
    <tr>
      <td>Both now     and as we expand our <font color="blue">manufacturing</font> <font color="blue">capacity</font>, we cannot be sure that our     <font color="blue">suppliers will furnish us with</font> required <font color="blue">components</font> when we need them</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">factors could</font> make it more <font color="blue">difficult</font> for us to <font color="blue"><font color="blue">effective</font>ly</font> and <font color="blue">efficiently</font>     <font color="blue">manufacture</font>  our  products,  and could <font color="blue">adversely</font> impact our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Some <font color="blue">suppliers may</font> be the only source for a particular component, which     makes us vulnerable to <font color="blue">cost increases</font> and supply <font color="blue">interruptions</font></td>
    </tr>
    <tr>
      <td>Vendors may     decide  to limit or <font color="blue">eliminate sales</font> of <font color="blue">certain products</font> to the medical     <font color="blue">industry due</font> to <font color="blue">product <font color="blue">liability</font></font> or other concerns, and we might not be     able to find a <font color="blue">suitable <font color="blue">replacement</font></font> for those products</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>of our     product  <font color="blue">components</font>  may  be  required to <font color="blue">comply with</font> the FDA or other     <font color="blue">regulatory</font> <font color="blue">manufacturing</font> regulations and to satisfy <font color="blue">regulatory</font> inspections     in <font color="blue">connection with</font> the <font color="blue">manufacture</font> of the <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>If we cannot obtain a     <font color="blue">necessary</font>  component,  we may need to find, test and obtain <font color="blue">regulatory</font>     approval for a <font color="blue">replacement</font> component, produce the component ourselves or     redesign the related product, which would cause <font color="blue"><font color="blue">significant</font> delay</font> and could     increase our <font color="blue">manufacturing</font> costs</td>
    </tr>
    <tr>
      <td>Any of these events could <font color="blue">adversely</font> impact     our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We own patents, trademarks, <font color="blue"><font color="blue">trade secret</font>s</font>, copyrights and other <font color="blue">intellectual</font>     property and know-how that we believe gives us a <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>If     we <font color="blue">cannot protect</font> our <font color="blue">intellectual</font> property, competition could force us to     lower our prices, which <font color="blue">could hurt</font> our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">intellectual</font> property rights</font> are and <font color="blue">will continue</font> to be a critical     component of our success</td>
    </tr>
    <tr>
      <td>A substantial portion of our <font color="blue">intellectual</font> property     rights relating to the AB5000, BVS 5000, Impella products, AbioCor, AbioCor     II and other products under <font color="blue">development</font> is in the form of <font color="blue"><font color="blue">trade secret</font>s</font>,     <font color="blue">rather than patents</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">preserve certain <font color="blue">proprietary</font></font> information as     trade  secrets,  we are required to <font color="blue">restrict disclosure</font> of information     intended to constitute <font color="blue"><font color="blue">trade secret</font>s</font> to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We protect our trade     secrets and <font color="blue"><font color="blue">proprietary</font> knowledge</font> in part <font color="blue">through confidentiality agreements</font>     with employees, <font color="blue">consultants</font> and other parties</td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">consultants</font>     and <font color="blue">third parties</font> with whom we have business <font color="blue">relationships</font> may also provide     services  to  other  parties in the medical device industry, including     companies, universities and <font color="blue">research organizations</font> that are developing     <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>In addition, some of our <font color="blue">former employees may seek</font>     <font color="blue">employment with</font>, and <font color="blue">become employed by</font>, our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>     that <font color="blue">confidentiality agreements with</font> our employees, <font color="blue">consultants</font> and third     <font color="blue">parties will</font> not be breached, that we will have <font color="blue">adequate remedies</font> for any     such  breach, or that our <font color="blue"><font color="blue">trade secret</font>s</font> will not <font color="blue">become known</font> to or be     <font color="blue">independently</font>  developed  by our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">trade secret</font>     protection for <font color="blue">technologies</font> or know-how relating to the AB5000, BVS 5000,     Impella products, <font color="blue">AbioCor or AbioCor II </font>could <font color="blue">adversely</font> affect our business     prospects</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">position will also depend</font> in part on our ability to defend our     existing and <font color="blue">future patents</font> and rights and conduct our business <font color="blue">activities</font>     free of <font color="blue">infringement</font> claims by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We intend to seek                                           13     ______________________________________________________________________       <font color="blue">additional</font> patents, but our pending and future patent <font color="blue">application</font>s may not     be  approved,  may  not  give us a <font color="blue">competitive</font> advantage, and could be     <font color="blue">challenged by others</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">proceedings</font> <font color="blue">in the US </font>and in other countries     may be expensive and time consuming</td>
    </tr>
    <tr>
      <td>In addition, patents issued by foreign     <font color="blue">countries may afford less protection than</font> is <font color="blue">available under</font> US patent     law, and may not <font color="blue">adequately protect</font> our <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> may <font color="blue">independently</font> develop <font color="blue">proprietary</font> <font color="blue">technologies</font> and     processes that are the same as or <font color="blue"><font color="blue">substantially</font> equivalent</font> to ours, or     <font color="blue">design around</font> our patents</td>
    </tr>
    <tr>
      <td><font color="blue">Companies  </font>in the medical device <font color="blue">industry typically</font> obtain patents and     <font color="blue">frequently</font> engage in substantial <font color="blue">intellectual</font> property litigation</td>
    </tr>
    <tr>
      <td>Our     products and <font color="blue">technologies</font> could infringe on the rights of others</td>
    </tr>
    <tr>
      <td>If a third     party <font color="blue">successfully</font> asserts a claim for <font color="blue">infringement</font> against us, we may be     liable  for substantial damages, be unable to sell products using that     <font color="blue">technology</font>, or have to seek a license or redesign the related product</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue"><font color="blue">alternative</font>s may</font> be uneconomical or impossible</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation could</font> be     costly, result in product <font color="blue">development</font> delays and divert the efforts and     attention of <font color="blue"><font color="blue">management</font> from</font> our business</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot attract</font> and retain the <font color="blue">management</font>, sales and other personnel we     need, we will not be successful</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend heavily on</font> the <font color="blue">contributions</font> of the <font color="blue">principal members</font> of our     business, financial, technical, sales and support, <font color="blue">regulatory</font> and clinical,     operating and <font color="blue">administrative <font color="blue">management</font></font> and staff, many of whom would be     <font color="blue">difficult</font> to replace</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for skilled and experienced business     <font color="blue">management</font>, scientific personnel and sales personnel in the <font color="blue">medical devices</font>     industry is intense</td>
    </tr>
    <tr>
      <td>If we lose the services of any of the <font color="blue">principal members</font>     of our <font color="blue">management</font> and staff, or if we are unable to attract and retain     qualified  personnel  in  the  future, especially scientific and sales     personnel, our business could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">grow rapidly</font> if our products under <font color="blue">development</font> advance through     the <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>The expansion of personnel and <font color="blue">facilities</font> will strain     our <font color="blue">management</font> and our financial and other resources</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot manage</font>     this growth <font color="blue">successfully</font>, our business <font color="blue">will likely suffer</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims could damage our reputation and hurt our financial     results</td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical use</font> of medical products, even after <font color="blue">regulatory</font> approval, poses     an <font color="blue">inherent risk</font> of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>We maintain limited product     <font color="blue">liability</font> <font color="blue">insurance coverage</font>, subject to <font color="blue">deductibles</font> and <font color="blue">exclusions</font></td>
    </tr>
    <tr>
      <td>We     cannot be sure that <font color="blue">product <font color="blue">liability</font></font> insurance will be available in the     future or will be <font color="blue">available on</font> acceptable terms or <font color="blue">at <font color="blue">reasonable cost</font>s</font>, or     that such insurance will provide us with adequate coverage against potential     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Claims against us, <font color="blue">regardless</font> of their merit or potential     outcome, may also hurt our ability to obtain <font color="blue">physician endorsement</font> of our     products or expand our business</td>
    </tr>
    <tr>
      <td>Many <font color="blue">patients supported by</font> our products do not survive</td>
    </tr>
    <tr>
      <td>There are many     <font color="blue">factors beyond</font> our control that could result in <font color="blue">patient death</font>, including the     condition  of  the  <font color="blue">patient prior</font> to use of the product, the skill and     re<font color="blue">liability</font> of physicians and <font color="blue">hospital personnel using</font> and monitoring the     product, and <font color="blue">product maintenance by customers</font></td>
    </tr>
    <tr>
      <td>However, the failure of the     <font color="blue">life support products</font> we distribute for <font color="blue">clinical test</font> or <font color="blue">sale could give</font>     rise to <font color="blue">product <font color="blue">liability</font></font> claims and <font color="blue">negative publicity</font></td>
    </tr>
    <tr>
      <td>The risk of <font color="blue">product <font color="blue">liability</font></font> claims <font color="blue">will increase as</font> we <font color="blue">introduce new</font>     products that are intended to support a <font color="blue">patient until</font> the end of life</td>
    </tr>
    <tr>
      <td>For     example, the AbioCor will have a <font color="blue">finite life</font> and could cause unintended     <font color="blue">complications</font> to other organs and may not be able to <font color="blue">successfully</font> support     all patients</td>
    </tr>
    <tr>
      <td>Its <font color="blue">malfunction could give rise</font> to <font color="blue">product <font color="blue">liability</font></font> claims     whether or not it has extended or improved the quality of the patient’s     life</td>
    </tr>
    <tr>
      <td>We cannot be sure that we can obtain <font color="blue">liability</font> insurance to cover the     AB5000, BVS 5000, Impella products, AbioCor or other <font color="blue">new products</font> at a     <font color="blue">reasonable cost</font>, if at all</td>
    </tr>
    <tr>
      <td>If we have to pay <font color="blue">product <font color="blue">liability</font></font> claims in     excess of our <font color="blue">insurance coverage</font>, our <font color="blue">financial condition</font> will be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________       Failure of our Impella <font color="blue">acquisition</font> to achieve its <font color="blue">potential benefits could</font>     harm our business and operating results</td>
    </tr>
    <tr>
      <td>The <font color="blue">acquisition</font> of our Impella division may not achieve its anticipated     benefits for a variety of reasons, including:           •   our <font color="blue">inability</font> to obtain FDA approval and market <font color="blue">acceptance</font> for     Impella’s products;           •   problems in <font color="blue">successfully</font> coordinating our research and <font color="blue">development</font>     efforts;           •   <font color="blue">difficult</font>y in <font color="blue">integrating</font> sales, support and <font color="blue">product marketing</font>;           •   costs and delays in <font color="blue">implementing common systems</font> and procedures,     including <font color="blue">financial accounting systems</font>; and           •   the <font color="blue">inability</font> to retain and integrate key <font color="blue">management</font>, research and     <font color="blue">development</font> and <font color="blue">customer support personnel</font></td>
    </tr>
    <tr>
      <td>Further, we <font color="blue">cannot assure</font> you that we will realize any of the anticipated     benefits and synergies of the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>Any one or all of the factors     identified  above  could  cause  increased operating costs, lower than     anticipated <font color="blue">financial performance</font>, or the loss of customers, employees or     business partners</td>
    </tr>
    <tr>
      <td>The failure to integrate Impella <font color="blue">successfully</font> would have     a material adverse effect on our business, <font color="blue">financial condition</font> and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The substantial costs of our Impella <font color="blue">acquisition</font> could harm our financial     results</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> our <font color="blue">acquisition</font> of Impella, we incurred substantial     costs</td>
    </tr>
    <tr>
      <td>These include fees to legal counsel, independent accountants and     <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>We may also be required to make <font color="blue"><font color="blue">additional</font> contingent payments</font>     under the terms of the <font color="blue">acquisition</font>, in an amount of up to <font color="blue">approximately</font>     dlra28dtta2 million, <font color="blue">based on</font> our <font color="blue">future stock price performance</font> and <font color="blue">milestones</font>     related  to  FDA approval and unit sales of Impella’s products</td>
    </tr>
    <tr>
      <td>If the     benefits of the <font color="blue">acquisition</font> do not exceed the <font color="blue">associated costs</font>, including     any dilution to our <font color="blue">stockholders</font> resulting from the issuance of shares of     our  <font color="blue">common stock</font> in the <font color="blue">transaction</font>, our financial results, including     <font color="blue">earnings per</font> share, <font color="blue">could suffer</font>, and the <font color="blue">market price</font> of our <font color="blue">common stock</font>     <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>If we acquire other companies or <font color="blue">businesses</font>, we will be subject to risks     that <font color="blue">could hurt</font> our business</td>
    </tr>
    <tr>
      <td>In  the future, we may pursue new <font color="blue">acquisition</font>s to obtain <font color="blue">complementary</font>     <font color="blue">businesses</font>, products or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Any such <font color="blue">acquisition</font> may not produce     the revenues, earnings or business synergies that we anticipated, and an     acquired business, product or <font color="blue">technology</font> might not perform as we expected</td>
    </tr>
    <tr>
      <td>If  we  pursue an <font color="blue">additional</font> <font color="blue">acquisition</font>, our <font color="blue">management</font> could spend a     <font color="blue"><font color="blue">significant</font> amount</font> of time and effort in identifying and completing the     <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>If we complete an <font color="blue">additional</font> <font color="blue">acquisition</font>, we <font color="blue">may encounter</font>     <font color="blue">significant</font> <font color="blue">difficult</font>ies and incur substantial expenses in <font color="blue">integrating</font> the     <font color="blue">operations</font> and personnel of the acquired company into our <font color="blue">operations</font> while     preserving the goodwill of the acquired company</td>
    </tr>
    <tr>
      <td>In particular, we may lose     the  services of <font color="blue">key employees</font> of the acquired company and we may make     changes in <font color="blue">management</font> that impair the acquired company’s <font color="blue">relationships</font> with     employees and customers</td>
    </tr>
    <tr>
      <td>Any  of these outcomes could prevent us from realizing the anticipated     benefits of our <font color="blue">additional</font> <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>To pay for an <font color="blue">acquisition</font>, we might     use stock or cash</td>
    </tr>
    <tr>
      <td>Alternatively, we <font color="blue">might borrow money from</font> a bank or other     lender</td>
    </tr>
    <tr>
      <td>If we use our stock, our <font color="blue">stockholders</font> would experience dilution of     their <font color="blue">ownership interests</font></td>
    </tr>
    <tr>
      <td>If we use cash or <font color="blue">debt financing</font>, our financial     <font color="blue">liquidity would</font> be reduced</td>
    </tr>
    <tr>
      <td>We may be required to <font color="blue">capitalize</font> a <font color="blue">significant</font>     amount of <font color="blue">intangibles</font>, including goodwill, which may lead to <font color="blue">significant</font>     <font color="blue">amortization charges</font></td>
    </tr>
    <tr>
      <td>In addition, we may incur <font color="blue">significant</font>, one-time write     offs and <font color="blue">amortization charges</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">amortization charges</font> and write offs     <font color="blue">could decrease</font> our <font color="blue">future earnings</font> or increase our <font color="blue">future losses</font></td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________       Our <font color="blue">rights <font color="blue">distribution</font></font>, <font color="blue">certificate</font> of <font color="blue">incorporation</font> and <font color="blue">Delaware </font>law could     make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us and <font color="blue">may prevent</font> our     <font color="blue">stockholders</font> from realizing a <font color="blue">premium on</font> our stock</td>
    </tr>
    <tr>
      <td>Our <font color="blue">rights <font color="blue">distribution</font></font> and provisions of our <font color="blue">certificate</font> of <font color="blue">incorporation</font>     and of the <font color="blue">Delaware </font>General Corporation Law may make it more <font color="blue">difficult</font> for a     <font color="blue">third party</font> to acquire us, even if doing so <font color="blue">would allow</font> our <font color="blue">stockholders</font> to     receive a <font color="blue">premium over</font> the prevailing <font color="blue">market price</font> of our stock</td>
    </tr>
    <tr>
      <td>Our rights     <font color="blue">distribution</font> and those provisions of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and     <font color="blue">Delaware </font>law are intended to <font color="blue">encourage potential acquirers</font> to <font color="blue">negotiate with</font>     us and allow our <font color="blue">Board of Directors </font>the <font color="blue">opportunity</font> to consider <font color="blue">alternative</font>     proposals in the interest of <font color="blue">maximizing stockholder value</font></td>
    </tr>
    <tr>
      <td>However, such     provisions may also discourage <font color="blue">acquisition</font> proposals or delay or prevent a     change in control, which could negatively affect our stock price</td>
    </tr>
    <tr>
      <td>The <font color="blue">market value</font> of our <font color="blue">common stock</font> could vary <font color="blue"><font color="blue">significant</font>ly</font>, <font color="blue">based on</font>     <font color="blue">market <font color="blue">perception</font>s</font> of the status of our <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>The <font color="blue">perception</font> of <font color="blue">securities analysts</font> regarding our product <font color="blue">development</font>     efforts could <font color="blue"><font color="blue">significant</font>ly</font> affect our stock price</td>
    </tr>
    <tr>
      <td>As a result, the market     price of our <font color="blue">common stock</font> has and could in the future change <font color="blue">substantially</font>     when  we  or  our <font color="blue"><font color="blue">competitor</font>s</font> make <font color="blue">product announcements</font></td>
    </tr>
    <tr>
      <td>Many factors     <font color="blue">affecting</font> our stock price are industry related and beyond our control</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">future success</font> is strongly dependent on <font color="blue">development</font> of new assist     products and implantable <font color="blue">replacement</font> heart devices</td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font> efforts     may not be successful</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently devoting</font> our <font color="blue">major research</font> and <font color="blue">development</font> and <font color="blue">regulatory</font>     efforts, and <font color="blue">significant</font> financial resources, to the <font color="blue">development</font> of the     AbioCor and AbioCor II, <font color="blue">product extensions</font> of <font color="blue">existing commercial products</font>     and <font color="blue">new products</font>, such as the <font color="blue">Impella Recover </font>2dtta5 and 5dtta0 micro <font color="blue">blood pumps</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of assist and <font color="blue">replacement</font> heart devices such as the AbioCor,     AbioCor II, Impella <font color="blue">blood pumps</font> and other <font color="blue">new products</font>, presents enormous     <font color="blue">challenges</font>  in  a  variety  of areas, many or all of which we may have     <font color="blue">difficult</font>y  in  overcoming, including blood compatible surfaces, blood     compatible flow, <font color="blue">manufacturing</font> techniques, pumping mechanisms, physiological     control,  energy  transfer,  anatomical  fit  and <font color="blue">surgical techniques</font></td>
    </tr>
    <tr>
      <td>Specifically, for many years, we and other parties have <font color="blue">been attempting</font> to     develop  a heart <font color="blue">replacement</font> device</td>
    </tr>
    <tr>
      <td>We cannot be sure that we will be     successful in our <font color="blue">development</font> efforts, and in the event that we are unable     to <font color="blue">commercialize</font> the AbioCor and AbioCor II, our business and financial     <font color="blue">condition could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>The markets for our products under <font color="blue">development</font> are unproven</td>
    </tr>
    <tr>
      <td>Even if our products are <font color="blue">successfully</font> developed and <font color="blue">approved by</font> the FDA and     <font color="blue">corresponding</font> foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>, they may not enjoy commercial     <font color="blue">acceptance</font> or success, which would <font color="blue">adversely</font> affect our business and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Several <font color="blue">factors could</font> limit our success, including:           •   our need to create a market for our <font color="blue">new products</font>: AB5000, AbioCor,     AbioCor II, Impella products and possible limited market <font color="blue">acceptance</font> among     physicians, <font color="blue">medical centers</font>, patients and <font color="blue">third party</font> payers;           •   the need for surgeons and <font color="blue">cardiologists</font> to develop or be trained in     new <font color="blue">surgical techniques</font> or non-invasive procedures in order to use our     products <font color="blue"><font color="blue">effective</font>ly</font>;           •   <font color="blue">limitations on</font> the number of patients who may have access to     physicians and <font color="blue">medical centers</font> with adequate training, equipment and     personnel to make use of our products;           •   <font color="blue">limitations inherent</font> in <font color="blue">first <font color="blue">generation</font> devices</font>, and the potential     failure to develop <font color="blue">successive <font color="blue">improvements</font></font>, including increases in service     life, which would reduce the <font color="blue">addressable market</font> for our products;           •   the <font color="blue">lifestyle limitations</font> that <font color="blue">patients will</font> have to accept;           •   the timing and amount of <font color="blue">reimbursement</font> for these products, if any, by     <font color="blue">third party</font> payers;                                           16     ______________________________________________________________________         •   the <font color="blue">introduction by</font> other companies of new <font color="blue">treatments</font>, products and     <font color="blue">technologies</font> which compete with our products, and may reduce their market     <font color="blue">acceptance</font>, or make <font color="blue">them obsolete</font>;           •   the reluctance, due to <font color="blue">ethical considerations</font>, of physicians, patients     and <font color="blue">society as</font> a whole to accept <font color="blue">significant</font> <font color="blue">medical devices</font> that replace or     assist the heart; and           •   the reluctance of physicians, patients and <font color="blue">society as</font> a whole to     accept the <font color="blue">finite life</font> and risk of <font color="blue">mechanical failure</font> of devices that     replace or assist the heart</td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of the AB5000, AbioCor, AbioCor II, <font color="blue">Impella Recover </font>    2dtta5 and 5dtta0 micro <font color="blue">blood pumps</font> and other <font color="blue">heart assist</font> <font color="blue">products will</font> require     <font color="blue">acceptance</font> by <font color="blue">cardiovascular surgeons</font> and <font color="blue">interventional</font> and <font color="blue">heart failure</font>     <font color="blue">cardiologists</font>, a limited number of whom <font color="blue"><font color="blue">significant</font>ly</font> influence medical     device selection and <font color="blue">purchasing decisions</font></td>
    </tr>
    <tr>
      <td>We may achieve our business     <font color="blue">objectives</font>  only if our other products are accepted and <font color="blue">recommended by</font>     leading physicians, which is likely to be <font color="blue">based on</font> a <font color="blue">determination by</font> these     physicians  that  our  products are safe, cost-<font color="blue">effective</font> and represent     acceptable methods of treatment</td>
    </tr>
    <tr>
      <td>Although we have developed <font color="blue">relationships</font>     <font color="blue">with leading cardiac surgeons</font> and <font color="blue">cardiologists</font>, we <font color="blue">cannot assure</font> that these     existing  <font color="blue">relationships</font> and <font color="blue">arrangements</font> can be maintained or that new     <font color="blue">relationships</font>  will  be  established  in  support  of our products</td>
    </tr>
    <tr>
      <td>If     <font color="blue">cardiovascular surgeons</font> and <font color="blue">cardiologists</font> do not consider our products to be     adequate for the treatment of our <font color="blue">target cardiac patient population</font> or if a     sufficient number of <font color="blue">physicians recommend</font> and use <font color="blue">competing products</font>, it     <font color="blue">would seriously harm</font> our business</td>
    </tr>
    <tr>
      <td>Testing of our <font color="blue">new products</font> will involve <font color="blue">uncertainties</font> and risks which could     delay or prevent new product <font color="blue">introductions</font>, require us to incur substantial     <font color="blue">additional</font> costs or result in our failure to bring our products to market</td>
    </tr>
    <tr>
      <td><font color="blue">Development  </font>and testing of design changes to the AbioCor, AbioCor II,     Impella 2dtta5 and 5dtta0 micro <font color="blue">blood pumps</font> and other products under <font color="blue">development</font>     is often extensive, expensive and time consuming</td>
    </tr>
    <tr>
      <td>Some of the tests for our     <font color="blue">products may</font> require months or years to perform, and we could be required to     begin  these tests again if we <font color="blue">modify one</font> of our products to correct a     problem identified in testing</td>
    </tr>
    <tr>
      <td>Even modest changes to certain <font color="blue">components</font> of     our products can take months or years to complete and test</td>
    </tr>
    <tr>
      <td>If results of     pre-clinical or <font color="blue">clinical test</font>ing of our products under <font color="blue">development</font> indicate     that design changes are required, such changes could cause <font color="blue">serious delays</font>     that would <font color="blue">adversely</font> affect our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>A number of companies     in the <font color="blue">medical industry</font> have suffered delays, cost overruns and project     <font color="blue">terminations despite</font> achieving promising results in pre-<font color="blue">clinical test</font>ing or     early  clinical  testing</td>
    </tr>
    <tr>
      <td>In the event that we suffer setbacks in the     pre-clinical  or  <font color="blue">clinical test</font>ing of our <font color="blue">heart assist</font> and <font color="blue">replacement</font>     products,  these <font color="blue">products may</font> be delayed, require <font color="blue">further funding</font>, and     <font color="blue">possibly may</font> not be brought to market</td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue">approval from</font> the FDA and/or from foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font>, we <font color="blue">cannot market</font> and sell the <font color="blue">affected products currently under</font>     <font color="blue">development</font> <font color="blue">in the US </font>and/or other countries</td>
    </tr>
    <tr>
      <td>If we cannot demonstrate through <font color="blue">clinical test</font>ing on humans or other means     that the AbioCor or other <font color="blue"><font color="blue">new products</font> under <font color="blue">development</font></font> and testing are     safe and <font color="blue">effective</font>, we will not be able to obtain <font color="blue">regulatory</font> approvals in     the US or other countries for the <font color="blue">commercial sale</font> of these products</td>
    </tr>
    <tr>
      <td>We     cannot  assure that the FDA or any other <font color="blue">regulatory</font> authority will act     quickly or <font color="blue">favorably on</font> our requests for this <font color="blue">product approval</font>, or that the     FDA  or  any other <font color="blue">regulatory</font> authority will not require us to provide     <font color="blue">additional</font> data that we do not currently anticipate in order to obtain     <font color="blue">product approval</font>s</td>
    </tr>
    <tr>
      <td>If we are successful in obtaining FDA approval for an HDE     for the AbioCor, the initial approval is likely to include <font color="blue">conditions</font> or     limitations to particular <font color="blue">indication</font>s that would limit the available market     for these products</td>
    </tr>
    <tr>
      <td>If we are not able to obtain <font color="blue">regulatory</font> approvals for     use  of the AbioCor or our other products under <font color="blue">development</font>, or if the     patient <font color="blue">populations</font> for which they are approved are not <font color="blue">sufficiently</font> broad,     the <font color="blue">commercial success</font> of these <font color="blue">products could</font> be limited</td>
    </tr>
    <tr>
      <td>We intend to market our <font color="blue">new products</font> in <font color="blue">international</font> markets, including the     <font color="blue">European Union and Japan</font></td>
    </tr>
    <tr>
      <td>We must obtain separate <font color="blue">regulatory</font> approvals in     order to market our products in other <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>The approval                                           17     ______________________________________________________________________       <font color="blue">process may differ among</font> those <font color="blue">jurisdictions</font> and approval <font color="blue">in the US </font>or in     any other jurisdiction does not <font color="blue">ensure approval</font> in other <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font>foreign approvals could result in <font color="blue"><font color="blue">significant</font> delay</font>s, <font color="blue">difficult</font>ies     and costs for us, and require <font color="blue">additional</font> trials and <font color="blue">additional</font> expense</td>
    </tr>
    <tr>
      <td>If we obtain <font color="blue">regulatory</font> approval of our <font color="blue">new products</font>, the <font color="blue">products will</font> be     subject to <font color="blue">continuing review</font> and extensive <font color="blue">regulatory</font> <font color="blue">requirements</font>, which     <font color="blue">could affect</font> the <font color="blue">manufacturing</font> and marketing of our products</td>
    </tr>
    <tr>
      <td>The FDA continues to <font color="blue">review products even</font> after they have received initial     approval</td>
    </tr>
    <tr>
      <td>If and when the FDA approves the <font color="blue">Impella and AbioCor </font>devices, or     our other products under <font color="blue">development</font>, the <font color="blue">manufacture</font> and marketing of these     <font color="blue">products will</font> be subject to <font color="blue">continuing regulation</font>, including <font color="blue">compliance with</font>     QSR, <font color="blue">adverse event</font> reporting <font color="blue">requirements</font> and <font color="blue">prohibitions on promoting</font> a     product for <font color="blue">unapproved uses</font></td>
    </tr>
    <tr>
      <td>We will also be required to obtain <font color="blue">additional</font> approvals in the event we     <font color="blue"><font color="blue">significant</font>ly</font> modify the design of an <font color="blue">approved product</font> or the product’s     labeling or <font color="blue">manufacturing</font> process</td>
    </tr>
    <tr>
      <td><font color="blue">Modifications </font>of this type are common     with <font color="blue">new products</font>, and we anticipate that the first <font color="blue">generation</font> of each of     our <font color="blue">products will</font> undergo a number of changes, <font color="blue">refinements</font> and <font color="blue">improvements</font>     over time</td>
    </tr>
    <tr>
      <td>For example, the current configuration of the AbioCor’s thoracic     unit, or “<font color="blue">replacement</font> heart,” is sized for <font color="blue">patients with relatively</font> large     <font color="blue">chest cavities</font>, and we anticipate that we will need to obtain <font color="blue">regulatory</font>     approval of <font color="blue">thoracic units</font> of other sizes</td>
    </tr>
    <tr>
      <td>If we are not able to obtain     <font color="blue">regulatory</font> approval of <font color="blue">modifications</font> to our current and <font color="blue">future products</font>, the     <font color="blue">commercial success</font> of these <font color="blue">products would</font> be limited</td>
    </tr>
    <tr>
      <td>We and our third-party suppliers of product <font color="blue">components</font> are also subject to     inspection  and  market  surveillance  by  the  FDA  for QSR and other     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Enforcement </font>actions resulting <font color="blue">from failure</font> to <font color="blue">comply with</font>     <font color="blue">government</font> <font color="blue">requirements</font> could result in fines, suspensions of approvals,     recalls of products, operating <font color="blue">restrictions</font> and <font color="blue">criminal prosecutions</font>, and     affect the <font color="blue">manufacture</font> and marketing of our products</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">could withdraw</font>     a  <font color="blue">previously</font>  approved  <font color="blue">product from</font> the <font color="blue">market upon receipt</font> of newly     discovered  information, including a failure to <font color="blue">comply with</font> <font color="blue">regulatory</font>     <font color="blue">requirements</font>,  the  occurrence of <font color="blue">unanticipated problems with products</font>     <font color="blue">following approval</font>, or other reasons, which could <font color="blue">adversely</font> affect our     operating results</td>
    </tr>
    <tr>
      <td>The cost of developing and <font color="blue">manufacturing</font> the AbioCor, AbioCor II, Impella     micro  <font color="blue">blood pumps</font> and other planned <font color="blue">new products</font> is substantial for a     company of our size and <font color="blue">might exert</font> a strain on our <font color="blue">available resources</font></td>
    </tr>
    <tr>
      <td>Spending on our AbioCor, AbioCor II, Impella micro <font color="blue">blood pumps</font> and other     products under <font color="blue">development</font> will remain <font color="blue">significant</font> for some time</td>
    </tr>
    <tr>
      <td>We expect     that  we  will  also need to make <font color="blue">significant</font> <font color="blue">expenditures</font> to begin to     <font color="blue">manufacture</font> and market the AbioCor and our other planned <font color="blue">new products</font> in     <font color="blue">commercial quantities</font> for sale <font color="blue">in the US </font>and other countries, if and when     we obtain <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>We cannot be sure that our estimates of     capital  <font color="blue">expenditures</font>  for the <font color="blue">development</font> of our <font color="blue">new products</font> will be     accurate</td>
    </tr>
    <tr>
      <td>We could have <font color="blue">significant</font> cost overruns, which could reduce our     ability  to  <font color="blue">commercialize</font>  our  products</td>
    </tr>
    <tr>
      <td>Any  delay or <font color="blue">inability</font> to     <font color="blue">commercialize</font> our products under <font color="blue">development</font> could <font color="blue">adversely</font> affect our     business prospects and results of <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>